Tocotrienol prodrug - VGI Health Technology
Alternative Names: IVB-002; IVB-004Latest Information Update: 16 Mar 2022
At a glance
- Originator Monash Institute of Pharmaceutical Sciences
- Developer Monash Institute of Pharmaceutical Sciences; VGI Health Technology
- Class Anti-inflammatories; Antifibrotics; Antineoplastics; Hepatoprotectants; Small molecules; Tocotrienols
- Mechanism of Action Antioxidants; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-alcoholic fatty liver disease; Pancreatic cancer
Most Recent Events
- 14 Feb 2022 VGI Health Technology executes a non-binding Term Sheet for the sale of Invictus Biopharma Pty Ltd Group (Invictus Group) to Invictus BioPharma Holdings Ltd (IVBHL)
- 14 Feb 2022 Monash Institute of Pharmaceutical Sciences plans formal preclinical studies in H2 of 2022
- 30 Jun 2021 VGI Health Technologies plans a clinical trial for Non-alcoholic fatty liver disease (PO) in 2023